Related Experiment Videos
Antenatal treatment of neonatal alloimmune thrombocytopenia
J B Bussel1, R L Berkowitz, J G McFarland
1Department of Pediatrics, Cornell University Medical Center, New York Hospital, NY 10021.
Insights
Intravenous gamma globulin (IVIG) therapy effectively treats neonatal alloimmune thrombocytopenia by increasing fetal platelet counts. This antenatal treatment helps prevent serious complications like intracranial hemorrhage in affected newborns.
Area of Science:
- Perinatology
- Immunology
- Hematology
Background:
- Neonatal alloimmune thrombocytopenia (NAIT) is an immune condition where maternal antibodies target fetal platelets.
- Intracranial hemorrhage (ICH) affects 15-20% of NAIT infants, with a 75% recurrence risk in subsequent pregnancies.
- Severe NAIT necessitates effective antenatal management to improve fetal outcomes.
Purpose of the Study:
- To evaluate the efficacy of antenatal treatment with intravenous gamma globulin (IVIG), with or without dexamethasone, for severe NAIT.
- To assess the impact of IVIG therapy on fetal platelet counts and the incidence of ICH.
- To determine the safety and long-term development of infants treated antenatally for NAIT.
Main Methods:
- Seven pregnant women with a history of severe NAIT received antenatal IVIG, with or without dexamethasone.
- Periumbilical blood sampling was performed in six fetuses to monitor platelet counts.
- Outcomes were compared to untreated affected siblings.
Main Results:
- A mean fetal platelet count increase of 72.5 +/- 62 x 10(9)/L was observed.
- All seven treated infants had birth platelet counts >30 x 10(9)/L, and none experienced ICH.
- Untreated siblings had lower platelet counts, and three experienced ICH (two antenatal).
Conclusions:
- Antenatal IVIG, with or without dexamethasone, is effective in raising fetal platelet counts in severe NAIT.
- This treatment strategy significantly reduces the risk of ICH in neonates with NAIT.
- Infants treated with IVIG showed normal development, indicating a favorable safety profile.
Abstract:
Neonatal alloimmune thrombocytopenia results from the formation of a maternal antibody to a paternal antigen on fetal platelets. Intracranial hemorrhage, which may be antenatal, occurs in approximately 15 to 20 percent of infants with this form of thrombocytopenia. In families with an affected infant, 75 percent of subsequent infants are affected. We report the results of antenatal treatment with intravenous gamma globulin, with or without dexamethasone, in seven pregnant women who had previously had infants who had severe alloimmune thrombocytopenia. The platelet count increased by a mean (+/- SD) of 72.5 +/- 62 x 10(9) per liter in the six fetuses in whom periumbilical blood sampling was performed. All seven treated fetuses had platelet counts above 30 x 10(9) at birth, and none had an intracranial hemorrhage, in contrast to all seven of their respective untreated siblings, who had lower platelet counts and three of whom had intracranial hemorrhages (antenatal in two infants). Mild intrauterine growth retardation was observed in one treated infant; all seven infants have developed normally in the two months to four years since birth. We conclude that intravenous gamma globulin, with or without dexamethasone, is effective in elevating the fetal platelet count in severe cases of neonatal alloimmune thrombocytopenia and in helping to avoid intracranial hemorrhage.